ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- University of Arkansas
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- This study will further evaluate the use of tumor markers (substances in body fluids that may be elevated as a consequence of certain diseases or conditions) in the diagnosis of breast and/or other cancers.
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This study will further evaluate the use of protein identification or protein pattern (signature) found in tears. We hypothesize that differences exist between the protein profile in tear fluid from patients with versus without cancer.
Detailed Description
Specifically, this study will compare the protein profile in tear fluid from patients with breast, ovarian or colon cancer versus "normal male and female patients" for differences that show promise as a diagnostic indicator. If such differences can be found, then their diagnostic potential will be assessed and developed further in a subsequent study. The long-term goal of this project will be to develop a screening tool for the detection of breast and/or other cancers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female or male, 18-100 years old
- •Patients who present for a routine check-up
- •Patients who present for the evaluation of an abnormal exam or test (mammogram, ultrasound, MRI, PET, etc.)
- •May or may not have a mass present
- •Patients who present for the evaluation of a palpable lump or mass
- •Patients may be pre or post biopsy for a mass, as long as there is a portion of the mass remaining
Exclusion Criteria
- •Patient \< 18 y/o or \> 100 y/o
- •Concurrent eye infection or trauma
- •Active conjunctivitis
- •Abnormal production of tears (too much or too little)
Outcomes
Primary Outcomes
This study will further evaluate the use of tumor markers (substances in body fluids that may be elevated as a consequence of certain diseases or conditions) in the diagnosis of breast and/or other cancers.
Time Frame: Collection of specimen and analysis with SELDI-MS